The cancer drugs included in this review were approved for the first time or received additional approvals by the US Food and Drug Administration in 2017 and are grouped here by several categories:
ALK indicates anaplastic lymphoma kinase; BLA, biologic license application; CDK, cyclin-dependent kinase; FDA, US Food and Drug Administration; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; IDH2, isocitrate dehydrogenase-2; NME, new molecular entity; NSCLC, non–small-cell lung cancer; PD-L1, programmed-cell death ligand 1; SSA, somatostatin analog; VTE, venous thromboembolism.
Return to Top
CAR indicates chimeric antigen receptor; DLBCL, diffuse large B-cell lymphoma; REMS, Risk Evaluation and Mitigation Strategy.
ALK indicates anaplastic lymphoma kinase; CAR, chimeric antigen receptor; CDK, cyclin-dependent kinase; dMMR, mismatch repair–deficient biomarker; EGFR, epidermal growth factor receptor; ER, estrogen receptor; FDA, US Food and Drug Administration; GIST, gastrointestinal stromal tumor; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; IL, interleukin; MEK, mitogen-activated extracellular signal-regulated kinase; MSI-H, microsatellite instability-high; NSCLC, non–small-cell lung cancer; PARP, poly (ADP-ribose) polymerase; PD-1/PD-L1, programmed-cell death receptor 1/ligand 1; Ph–, Philadelphia chromosome–negative; Ph+, Philadelphia chromosome–positive; REMS, Risk Evaluation and Mitigation Strategy; VEGF, vascular endothelial growth factor.
HER2 indicates human epidermal growth factor receptor 2; PARP, poly (ADP-ribose) polymerase.